STOCK TITAN

Pasithea Therapeutics Corp - KTTA STOCK NEWS

Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: ktta), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.

Pasithea Therapeutics Corp (NASDAQ: KTTA) is a clinical-stage biotechnology company advancing novel therapies for central nervous system disorders and genetic conditions. This dedicated news hub provides investors and industry observers with timely updates on the company's scientific progress, regulatory milestones, and strategic initiatives.

Our curated collection offers comprehensive tracking of KTTA's developments including clinical trial updates for its lead candidate PAS-004, research collaborations, and advancements in treating conditions like Neurofibromatosis Type 1 and ALS. The content is organized to help stakeholders efficiently monitor the company's progress in neuroscience innovation and drug development.

Key updates cover regulatory filings, partnership announcements, peer-reviewed research publications, and clinical trial results. All content maintains strict editorial standards to ensure accuracy and relevance for both professional investors and those new to biotech equities.

Bookmark this page for centralized access to verified information about Pasithea's therapeutic pipeline, including its work on MEK inhibitors and translational medicine approaches. Check back regularly for essential updates that could impact long-term research trajectories and market positioning.

Rhea-AI Summary
Pasithea Therapeutics Corp. (KTTA) announced positive preclinical results for PAS-004, a potential treatment for Central Nervous System disorders. PAS-004 demonstrated superior anti-tumor efficacy in lung and liver cancer models compared to FDA-approved MEK inhibitors. The company plans to start a Phase 1 trial in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.33%
Tags
none
-
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) adjourns its annual meeting of stockholders to December 19, 2023, to allow additional time for stockholders to vote on proposals outlined in the Proxy Statement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.91%
Tags
none
-
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) plans to submit PAS-004 IND application in the current quarter and begin a Phase 1 dose escalation trial in advanced solid tumor patients harboring RAS, RAF, and NF1 mutations. The FDA's positive feedback and guidance include a recommendation to begin dosing in patients who will benefit from treatment rather than in healthy volunteers. PAS-004 was granted orphan drug designation for the treatment of NF1 in November 2020. Dr. Tiago Reis Marques, CEO of Pasithea, expressed excitement to begin testing PAS-004 in a first-in-human Phase 1 dose escalation trial in early 2024 following acceptance of the IND by the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the selection of a lead therapeutic candidate for its PAS-003 program, a humanized monoclonal antibody targeting α5β1 integrin, showing promise for the treatment of ALS. The antibody has been optimized for high affinity and specificity, ready for manufacturing and IND-enabling studies. Extensive preclinical studies have validated the candidate's efficacy in both sporadic and familial ALS mouse models, with potential implications for human patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Pasithea Therapeutics Corp. completes tender offer, purchasing all 5,323,451 shares at $0.70 per share
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
-
Rhea-AI Summary
Pasithea Therapeutics Corp. to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.2%
Tags
conferences
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced a publication in the Proceedings of the National Academy of Sciences related to its PAS-003 drug discovery program targeting α5/β1 integrin for the treatment of amyotrophic lateral sclerosis (ALS). The study reveals increased integrin expression in ALS patient tissues, specificity of α5 integrin in ALS, and the efficacy of a monoclonal antibody against α5 integrin in improving survival and motor function in the SOD1G93A mouse model of ALS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
-
Rhea-AI Summary
Pasithea Therapeutics Corp. announces a $4.0 million tender offer to repurchase up to 5.7 million shares of its common stock at $0.70 per share. The offer is expected to close in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.9%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.9%
Tags
none
Rhea-AI Summary
Pasithea Therapeutics Corp. confirms that its Board of Directors has formed a special committee to evaluate an unsolicited proposal from Lucy Scientific Discovery Inc. to acquire all outstanding shares of Pasithea common stock. The committee is actively evaluating the proposal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
management
Pasithea Therapeutics Corp

Nasdaq:KTTA

KTTA Rankings

KTTA Stock Data

3.73M
2.46M
19.08%
6.09%
0.69%
Biotechnology
Pharmaceutical Preparations
Link
United States
MIAMI BEACH